Imurel (Azathioprine)

Azathioprine is a prodrug that is converted to 6‑mercaptopurine inside cells. This metabolite interferes with purine synthesis, blocking DNA replication and thereby inhibiting the proliferation of T and B lymphocytes, which reduces immune activity.

The dose of Imurel is individualized by the prescribing clinician based on the specific indication, patient weight, renal and hepatic function, and laboratory monitoring results. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

The safety of azathioprine in pregnancy or while breastfeeding is not definitively established. Healthcare providers weigh potential benefits against possible risks to the fetus or infant, and a decision is made on a case‑by‑case basis.

To request Imurel, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with calcineurin inhibitors such as cyclosporine, azathioprine has a different mechanism—targeting purine synthesis rather than calcineurin signaling. It is often chosen for its oral administration and lower nephrotoxicity, but monitoring for bone‑marrow suppression is essential.

Imurel should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not store in bathrooms or other humid areas.

Imurel is taken orally, usually with food or a glass of water to reduce gastrointestinal irritation. The exact timing and frequency are determined by the prescriber, who may adjust the regimen based on therapeutic response and laboratory monitoring.

Serious risks include severe bone‑marrow suppression leading to pancytopenia, life‑threatening infections, hepatotoxicity, pancreatitis, and an increased long‑term risk of certain malignancies such as lymphoma. Regular blood and liver‑function monitoring is essential to detect these complications early.

Imurel is contraindicated in patients with known hypersensitivity to azathioprine or its metabolites, those with severe bone‑marrow failure, active uncontrolled infections, or significant liver disease. It should also be used with caution in pregnant or breastfeeding individuals after a risk‑benefit assessment.